文献速递淋巴瘤造血干细胞移植与细胞治疗

成人T细胞白血病/淋巴瘤移植后复发/难治生存改善的真实世界研究

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience.
PubMed 文献 · Br J Haematol · 2026-06-15

该研究基于全国数据库纳入1146例成人T细胞白血病/淋巴瘤(ATL)异基因造血干细胞移植后复发/难治患者,跨24年分三个时期分析。结果显示,难治患者晚期(2017-2022)总死亡率较早期(1999-2010)显著降低(HR 0.73),复发患者中、晚期总死亡率均显著低于早期(HR 0.62、0.68)。

要点

  • 移植后难治ATL晚期总死亡率较早期显著降低(HR 0.73)。
  • 移植后复发ATL中晚期总死亡率均显著低于早期(HR 0.62、0.68)。
  • 近年治疗进步可能增加干预机会并改善移植后R/R ATL生存。

核心结论

  • 近期治疗进展可能增加治疗干预机会,从而改善移植后复发/难治ATL患者的生存结局。

研究设计与样本

  • 基于全国数据库的回顾性研究,纳入1146例异基因造血干细胞移植后复发/难治的ATL患者,跨24年分为1999-2010(早期,参照)、2011-2016(中期)、2017-2022(晚期)三组。

主要发现

  • 难治患者中,晚期总死亡率较早期显著降低(HR 0.73,95%CI 0.55-0.96),早期与中期无显著差异。
  • 复发患者中,中期总死亡率较早期显著降低(HR 0.62,95%CI 0.48-0.80)。
  • 复发患者中,晚期总死亡率较早期显著降低(HR 0.68,95%CI 0.52-0.90)。

临床怎么用

  • 对于移植后复发/难治的ATL患者,近年治疗进步可能为再次干预提供更多机会,应积极评估 salvage 治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) offers potentially curative outcomes for adult T-cell leukaemia/lymphoma (ATL), but post-transplant refractory/relapsed (R/R) ATL is associated with poor outcomes. Advances have been made in transplant modalities, novel targeted agents and supportive care; however, it remains unclear whether these advances have improved survival outcomes of post-transplant R/R ATL. To clarify changes in survival after post-transplant R/R, we evaluated the survival outcomes in 1146 patients over a 24-year period, using a nationwide database. The period was divided into three groups: 1999-2010 (early period, as reference), 2011-2016 (middle period) and 2017-2022 (late period). In patients with refractory ATL, multivariate analyses showed no significant difference in overall mortality (OM) after post-transplant refractory in the early and middle periods, but a significantly lower OM in the late period than in the early period (hazard ratio [HR], 0.73 [95% confidence interval, 0.55-0.96]). In patients with relapsed ATL, OM after post-transplant relapse was significantly lower in the middle (HR 0.62 [0.48-0.80]) and late periods (HR 0.68 [0.52-0.90]) than in the early period. Thus, recent advances appear to have contributed to increased opportunities for therapeutic interventions, leading to improved survival outcomes in patients with post-transplant R/R ATL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Itonaga H, Fukushima T, Kato K, et al. Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience. Br J Haematol. 2026. PMID: 42298882. doi:10.1111/bjh.70631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。